

Supplementary Table 6: IBD-related HCRU and costs in CD patients with 2L advanced treatment, up to 6 years of follow-up, pairwise comparison with IFX as reference after IPW adjustment.

Health economic outcome parameters PPY	ADA (n=79) vs. IFX ¹	p-value ²	UST (n=79) vs. IFX ¹	p-value ²	VDZ (n=79) vs. IFX ¹	p-value ²
Number of IBD-related hospitalizations (events)	0.29 (0.74) vs. 0.39 (0.74)	0.4	0.20 (0.43) vs. 0.38 (0.74)	0.065	0.32 (1.11) vs. 0.43 (0.76)	0.5
Duration of IBD-related hospital stays (days)	1.9 (4.9) vs. 2.6 (4.5)	0.3	1.9 (7.3) vs. 2.6 (4.6)	0.3	2.6 (14.1) vs. 2.7 (4.4)	>0.9
Number of IBD-related surgeries (events)	0.28 (0.89) vs. 0.32 (0.61)	0.7	0.40 (1.57) vs. 0.30 (0.61)	0.4	0.24 (0.75) vs. 0.29 (0.61)	0.7
Duration of IBD-related sick-leave (days)	18 (34) vs. 21 (35)	0.7	33 (61) vs. 21 (36)	0.2	24 (63) vs. 23 (36)	0.8
Number of IBD-related sick-leave (events)	0.85 (1.07) vs. 2.19 (2.86)	0.005	0.91 (1.10) vs. 2.39 (2.96)	0.003	1.34 (2.18) vs. 2.29 (2.85)	0.050
Costs for IBD-specific hospitalizations (EUR)	959 (2,713) vs. 1,518 (2,860)	0.2	1,365 (6,183) vs. 1,537 (2,920)	0.7	1,089 (4,150) vs. 1,596 (2,841)	0.3
Costs for IBD-specific medication (EUR)	19,567 (15,218) vs. 24,558 (13,851)	0.024	39,337 (13,659) vs. 25,021 (14,129)	<0.001	24,120 (10,197) vs. 25,133 (14,603)	0.6
Costs for IBD-specific outpatient treatment (EUR)	789 (555) vs. 1,059 (542)	<0.001	833 (464) vs. 1,074 (550)	<0.001	1,121 (586) vs. 1,083 (556)	0.7
Total costs for IBD-specific treatment (EUR)	21,406 (15,690) vs. 27,254 (14,002)	0.012	41,639 (14,882) vs. 27,753 (14,227)	<0.001	26,364 (10,985) vs. 27,917 (14,629)	0.4
Total costs for all-cause treatment (EUR)	38,269 (41,043) vs. 36,171 (35,470)	0.7	70,238 (49,986) vs. 36,740 (36,485)	<0.001	35,183 (33,847) vs. 37,399 (38,224)	0.6

ADA= Adalimumab CD = Crohn's disease IBD = Inflammatory bowel disease IFX = Infliximab IPW = inverse probability weighting HCRU = Healthcare resource utilization PPY = Per Patient Year UST= Ustekinumab VDZ= Vedolizumab

¹Mean (SD), in ADA/UST/VDZ vs. IFX in 2L CD patients

²Regression least-squares mean differences